[CHMA] Chiasma, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.15 Change: 0.1 (4.88%)
Ext. hours: Change: 0 (0%)

chart CHMA

Refresh chart

Strongest Trends Summary For CHMA

CHMA is in the medium-term down -10% in 1 month. In the long-term up 227% in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities35.63 M Cash From Investing Activities10 K Cash From Operating Activities-4.92 M Gross Profit
Net Profit-4.24 M Operating Profit-4.15 M Total Assets72.64 M Total Current Assets71.32 M
Total Current Liabilities3.78 M Total Debt Total Liabilities8.5 M Total Revenue
Technical Data
High 52 week8.08 Low 52 week1.25 Last close5.07 Last change0.8%
RSI38.99 Average true range0.69 Beta0.82 Volume174.71 K
Simple moving average 20 days-11.54% Simple moving average 50 days-25.36% Simple moving average 200 days-1.72%
Performance Data
Performance Week0% Performance Month-23.18% Performance Quart-23.3% Performance Half49.12%
Performance Year290% Performance Year-to-date63.02% Volatility daily7.84% Volatility weekly17.53%
Volatility monthly35.93% Volatility yearly124.46% Relative Volume300.96% Average Volume772.68 K
New High New Low

News

2019-09-18 06:30:00 | 3 Small Biotechs With Favorable Risk Vs. Reward Profiles

2019-09-17 09:00:01 | What Makes Chiasma CHMA a New Buy Stock

2019-09-13 08:19:53 | What Kind Of Shareholder Owns Most Chiasma, Inc. NASDAQ:CHMA Stock?

2019-09-05 16:05:00 | Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly

2019-08-16 09:00:01 | Chiasma CHMA Upgraded to Buy: Here's Why

2019-08-09 17:03:26 | Edited Transcript of CHMA earnings conference call or presentation 8-Aug-19 9:00pm GMT

2019-08-09 13:23:30 | Chiasma Inc CHMA Q2 2019 Earnings Call Transcript

2019-08-08 16:05:00 | Chiasma Reports Second Quarter 2019 Results

2019-08-01 16:05:00 | Chiasma to Report Second Quarter Financial Results on August 8, 2019

2019-07-31 13:48:03 | Steven Cohen Charges Into Chiasma

2019-07-26 09:06:25 | Chiasma Announces Pricing of Underwritten Public Offering of $55.0 Million of Common Stock

2019-07-25 16:01:00 | Chiasma Announces Proposed Offering of Common Stock

2019-07-23 09:39:35 | Here Is What's Driving The Rally In Chiasma

2019-07-23 06:00:00 | Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa® for the Maintenance Treatment of Adults with Acromegaly

2019-07-15 12:55:11 | One Thing To Remember About The Chiasma, Inc. NASDAQ:CHMA Share Price

2019-06-28 14:19:40 | 18 Stocks Joining The Russell Indices

2019-06-28 07:32:52 | The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO

2019-06-27 16:10:00 | Chiasma Set to Join Russell 3000® Index

2019-06-27 16:05:00 | Chiasma Provides Update on Ongoing Mycapssa® Phase 3 Clinical Trials

2019-06-06 07:37:34 | The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

2019-06-05 16:05:00 | Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®

2019-05-30 08:50:12 | Chiasma CHMA Catches Eye: Stock Jumps 9.7%

2019-05-30 05:59:09 | Will Chiasma to Surge Higher?

2019-05-14 16:05:00 | Chiasma and Lonza Announce Progression of Oral Octreotide Capsules Development and Definitive Commercial Supply Agreement

2019-05-10 18:07:59 | Edited Transcript of CHMA earnings conference call or presentation 9-May-19 9:00pm GMT

2019-05-09 18:45:44 | Chiasma: 1Q Earnings Snapshot

2019-05-09 16:05:00 | Chiasma Reports First Quarter 2019 Results

2019-04-30 16:05:00 | Chiasma to Report First Quarter Financial Results on May 9, 2019

2019-04-25 14:14:04 | Shareholders Are Raving About How The Chiasma NASDAQ:CHMA Share Price Increased 312%

2019-04-03 09:25:00 | Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters’ Option

2019-03-29 09:25:00 | Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock

2019-03-28 17:19:31 | 5 Stocks Moving In Thursday's After-Hours Session

2019-03-28 16:01:00 | Chiasma Announces Proposed Offering of Common Stock

2019-03-21 16:05:00 | Chiasma Announces Three Poster Presentations at ENDO 2019

2019-03-08 16:05:00 | Chiasma Reports Fourth Quarter and Year End 2018 Results

2019-03-04 16:05:00 | Chiasma to Participate in Three Investor Conferences in March

2019-02-28 08:00:00 | Chiasma Announces Support for Rare Disease Day 2019

2019-02-27 12:56:56 | Have Insiders Been Buying Chiasma, Inc. NASDAQ:CHMA Shares?

2019-01-03 16:05:00 | Chiasma Previews Important Upcoming Milestones

2018-12-21 09:47:02 | Do Directors Own Chiasma, Inc. NASDAQ:CHMA Shares?

2018-11-21 08:55:00 | Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-08 18:03:30 | Chiasma: 3Q Earnings Snapshot

2018-11-08 16:05:00 | Chiasma Reports Third Quarter 2018 Results

2018-11-01 08:00:00 | Chiasma Supports Acromegaly Awareness Day

2018-10-17 16:05:00 | Chiasma Announces Oral Presentation at the 18th Congress of the European Neuroendocrine Association

2018-10-02 09:10:25 | The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

2018-10-01 16:01:00 | Chiasma Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

2018-09-20 13:57:56 | One Thing To Consider Before Buying Chiasma Inc NASDAQ:CHMA

2018-09-13 16:01:00 | Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies

2018-08-09 17:47:39 | Chiasma: 2Q Earnings Snapshot